A New Way to Prevent Complications After Bone Marrow Transplant
BMT CTN Core - University of Minnesota
This project explores a new medication combination to prevent graft-versus-host disease and cancer relapse after a bone marrow transplant.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11167659 on NIH RePORTER |
What this research studies
After a bone marrow transplant, patients face challenges like graft-versus-host disease (GVHD) and the return of their cancer. This project tests a new approach to prevent both by changing the standard medication regimen. We are replacing one common drug, mycophenolate mofetil (MMF), with a new oral medication called VIC-1911. This new drug is designed to both reduce GVHD and directly fight cancer cells, potentially offering a better outcome for patients.
Who could benefit from this research
Good fit: Ideal candidates are adults with blood cancers who are undergoing a myeloablative allogeneic hematopoietic cell transplant.
Not a fit: Patients who are not receiving an allogeneic hematopoietic cell transplant or who do not have hematologic malignancies would not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new treatment could lead to fewer cases of graft-versus-host disease and a lower chance of cancer returning after a bone marrow transplant.
How similar studies have performed: Early preclinical and phase I human data from the University of Minnesota show promising results with this combined regimen, suggesting low rates of acute/chronic GVHD and relapse.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Juckett, Mark — University of Minnesota
- Study coordinator: Juckett, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.